Market capitalization | SEK33.53b |
Enterprise Value | SEK30.70b |
P/E (TTM) P/E ratio | 77.50 |
EV/FCF (TTM) EV/FCF | 85.18 |
EV/Sales (TTM) EV/Sales | 16.44 |
P/S ratio (TTM) P/S ratio | 17.95 |
P/B ratio (TTM) P/B ratio | 10.19 |
Revenue growth (TTM) Revenue growth | 8.78% |
Revenue (TTM) Revenue | SEK1.87b |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
6 Analysts have issued a Camurus forecast:
6 Analysts have issued a Camurus forecast:
Dec '24 |
+/-
%
|
||
Revenue | 1,868 1,868 |
9%
9%
|
|
Gross Profit | 1,723 1,723 |
9%
9%
|
|
EBITDA | 485 485 |
11%
11%
|
EBIT (Operating Income) EBIT | 471 471 |
12%
12%
|
Net Profit | 428 428 |
1%
1%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.
Head office | Sweden |
CEO | Sven Tiberg |
Employees | 223 |
Founded | 2004 |
Website | www.camurus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.